Yuan T - Search Results

1

A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

Zhang H, Liu M, Xiao X, Lv H, Jiang Y, Li X, Yuan T, Zhao M. Zhang H, et al. Among authors: yuan t. Leuk Lymphoma. 2022 Jun;63(6):1418-1427. doi: 10.1080/10428194.2022.2030476. Epub 2022 Feb 1. Leuk Lymphoma. 2022. PMID: 35105265 Free article.

2

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.

He X, Xiao X, Li Q, Jiang Y, Cao Y, Sun R, Jin X, Yuan T, Meng J, Ma L, Lu W, Lyu C, Liu K, Zhao M. He X, et al. Among authors: yuan t. Leukemia. 2019 Aug;33(8):2102-2104. doi: 10.1038/s41375-019-0437-5. Epub 2019 Mar 7. Leukemia. 2019. PMID: 30846865 Free PMC article. No abstract available.

3

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.

Cao Y, Lu W, Sun R, Jin X, Cheng L, He X, Wang L, Yuan T, Lyu C, Zhao M. Cao Y, et al. Among authors: yuan t. Front Oncol. 2019 Aug 19;9:767. doi: 10.3389/fonc.2019.00767. eCollection 2019. Front Oncol. 2019. PMID: 31482064 Free PMC article.

4

Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation.

Lyu H, Lu W, Yao J, Xiao X, Li Q, Wang J, Mu J, Qi Y, Zhu H, Jiang Y, Li X, Meng J, Yuan T, He X, Jiang E, Han M, Zhao M. Lyu H, et al. Among authors: yuan t. Leuk Lymphoma. 2020 Apr;61(4):840-847. doi: 10.1080/10428194.2019.1695053. Epub 2019 Nov 28. Leuk Lymphoma. 2020. PMID: 31777304

5

Case Report of Anti-CD123 Chimeric Antigen Receptor T-Cell Therapy Followed by Radiotherapy for a Recurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem Cell Transplantation.

Jiang YL, Li Q, Yuan T, Jiang YY, Deng Q. Jiang YL, et al. Among authors: yuan t. Onco Targets Ther. 2020 Apr 22;13:3425-3430. doi: 10.2147/OTT.S250016. eCollection 2020. Onco Targets Ther. 2020. PMID: 32368098 Free PMC article.

6

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.

Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, Jiang Y, Zhang H, Li X, Jiang Y, Meng J, Yuan T, Zhu H, He X, Jin X, Sun R, Sui T, Liu K, Zhao M. Lu W, et al. Among authors: yuan t. Cancer Immunol Immunother. 2021 Dec;70(12):3501-3511. doi: 10.1007/s00262-021-02941-4. Epub 2021 Apr 25. Cancer Immunol Immunother. 2021. PMID: 33899130 Free PMC article. Clinical Trial.

7

Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.

Wei Y, Xiong X, Li X, Lu W, He X, Jin X, Sun R, Lyu H, Yuan T, Sun T, Zhao M. Wei Y, et al. Among authors: yuan t. Cancer Sci. 2021 Sep;112(9):3636-3644. doi: 10.1111/cas.15048. Epub 2021 Jul 21. Cancer Sci. 2021. PMID: 34185931 Free PMC article.

8

[Effect and Involved Mechanism of RSL3-induced Ferroptosis in Acute Leukemia Cells MOLM13 and Drug-resistant Cell Lines].

Cheng L, Jin X, Lu WY, Sun R, Cao YQ, Wei YX, Wang LQ, He XY, Yuan T, Meng JX, Zhao MF. Cheng L, et al. Among authors: yuan t. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug;29(4):1109-1118. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.014. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. PMID: 34362489 Chinese.

9

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.

Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, Yuan J, Wang X, Wang Y, Deng Q. Deng H, et al. Among authors: yuan t, yuan j. Front Immunol. 2021 Aug 5;12:720571. doi: 10.3389/fimmu.2021.720571. eCollection 2021. Front Immunol. 2021. PMID: 34421924 Free PMC article.

10

Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.

Li W, Liu M, Yuan T, Yan L, Cui R, Deng Q. Li W, et al. Among authors: yuan t. Hematol Oncol. 2022 Apr;40(2):223-232. doi: 10.1002/hon.2958. Epub 2022 Jan 10. Hematol Oncol. 2022. PMID: 34942032 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,310 results

Search Page

Filters